As of 2025-06-04, the Intrinsic Value of Bicara Therapeutics Inc (BCAX) is -9.61 USD. This BCAX valuation is based on the model Peter Lynch Fair Value. With the current market price of 9.90 USD, the upside of Bicara Therapeutics Inc is -197.08%.
Based on its market price of 9.90 USD and our intrinsic valuation, Bicara Therapeutics Inc (BCAX) is overvalued by 197.08%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -9.61 - -9.61 | -9.61 | -197.08% |
| DDM - Stable | (8.37) - (16.41) | (12.39) | -225.1% |
| DDM - Multi | (4.17) - (6.51) | (5.09) | -151.5% |
| Market Cap (mil) | 539.95 |
| Beta | 1.66 |
| Outstanding shares (mil) | 54.54 |
| Enterprise Value (mil) | 77.88 |
| Market risk premium | 4.60% |
| Cost of Equity | 17.31% |
| Cost of Debt | 5.00% |
| WACC | 11.16% |